Spread the loveWayne Lumbasi A groundbreaking agreement is set to make a twice yearly HIV prevention injection dramatically cheaper for countries hardest hit by the epidemic. Under the deal, Gilead Sciences has granted voluntary licences to six generic drugmakers including India’s Dr Reddy’s and Hetero Labs to produce lenacapavir, a long acting pre exposure prophylaxis … Continue reading LANDMARK DEAL PAVES WAY FOR CHEAPER HIV PROTECTION JAB